| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066942 | MAINPOINTE | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Jan, 2032
(8 years from now) | |
| US9107921 | MAINPOINTE | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
Jan, 2032
(8 years from now) | |
Tuxarin Er is owned by Mainpointe.
Tuxarin Er contains Chlorpheniramine Maleate; Codeine Phosphate.
Tuxarin Er has a total of 2 drug patents out of which 0 drug patents have expired.
Tuxarin Er was authorised for market use on 22 June, 2015.
Tuxarin Er is available in tablet, extended release;oral dosage forms.
Tuxarin Er can be used as treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets.
The generics of Tuxarin Er are possible to be released after 03 January, 2032.
Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient
Market Authorisation Date: 22 June, 2015
Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets
Dosage: TABLET, EXTENDED RELEASE;ORAL
TUXARIN ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic